NCT00530569Unknown不适用
Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin Therapy
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 60
- 试验地点
- 1
研究概览
简要总结
About 30% of breast cancers have higher than normal levels of a cellular marker called HER2. The amount of HER2 is often measured in breast tissue. A higher level of this marker usually indicates a more aggressive type of breast cancer. Cytokeratin is a second cellular marker found in breast cancer cells. Detection of Circulating cytokeratin in the blood could indicate the presence of cancer. The Pathology Department of the Tom Baker Cancer Center is doing this study to see if measuring the levels of circulating HER2 and cytokeratin, through blood testing has clinical significance for patients with breast cancer.
详细描述
- Single Variate analysis will be performed to correlate variables such as tumour size, grade, stage, ER status, PR status and biopsy HER2 status with soluble HER2 levels.
- Soluble HER2 levels will be analyzed as both a continuous and categorized variable.
- The analysis will attempt to discern the relationship between soluble HER2 levels, HER2 positive circulating epithelial cell level and treatment response.
- This will provide evidence of the effect various treatments have on HER2 levels. HER2 levels both in patients treated with Herceptin and those on other treatment protocols, will be related to clinical disease measures such as time to progression, time to failure, duration of response and duration of survival.
- An initial model of the relationship between these factors and soluble HER2 as a marker will be established from the data.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Albertan women with breast cancer who will undergo Herceptin therapy as part of their treatment at some point during a one-year period.
排除标准
- •Greater than 80 years of age
- •Previous cancer diagnosis - (other than skin cancer)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901HER2+ CancerNCT01526473H. Kim Lyerly22
已完成
不适用
Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinEProgress-free SurvivalOverall Response RateAdverse EventsNCT01291667Shanghai CP Guojian Pharmaceutical Co., Ltd.330
Unknown
不适用
Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and TaxanesCardiotoxicity.Anti Her2 Therapy.Metastatic Breast CancerNCT02101879Rambam Health Care Campus20
招募中
不适用
Identification of Risk Factors for Brain Recurrence in Patients With HER2-positive Localised Breast CancerHER2-positive Breast CancerNCT06358625Center Eugene Marquis120
尚未招募
不适用
Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast CancerHER 2 Low-expressing Breast CancerNCT06492447Tianjin Medical University Cancer Institute and Hospital50